| Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling M Felcht, R Luck, A Schering, P Seidel, K Srivastava, J Hu, A Bartol, ... The Journal of clinical investigation 122 (6), 1991-2005, 2012 | 504 | 2012 |
| Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes KM Kortüm, EK Mai, NH Hanafiah, CX Shi, YX Zhu, L Bruins, S Barrio, ... Blood, The Journal of the American Society of Hematology 128 (9), 1226-1233, 2016 | 246 | 2016 |
| Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial H Goldschmidt, HM Lokhorst, EK Mai, B van der Holt, IW Blau, ... Leukemia 32 (2), 383-390, 2018 | 217 | 2018 |
| Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma EK Mai, U Bertsch, J Dürig, C Kunz, M Haenel, IW Blau, M Munder, ... Leukemia 29 (8), 1721-1729, 2015 | 201 | 2015 |
| Angiopoietin-2 is critical for cytokine-induced vascular leakage AV Benest, K Kruse, S Savant, M Thomas, AM Laib, EK Loos, U Fiedler, ... PloS one 8 (8), e70459, 2013 | 198 | 2013 |
| Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project M D'agostino, DA Cairns, JJ Lahuerta, R Wester, U Bertsch, A Waage, ... Journal of clinical oncology 40 (29), 3406-3418, 2022 | 187 | 2022 |
| Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation J Xu, N Pfarr, V Endris, EK Mai, NH Md Hanafiah, N Lehners, R Penzel, ... Oncogenesis 6 (5), e337-e337, 2017 | 87 | 2017 |
| Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial M Merz, H Salwender, M Haenel, EK Mai, U Bertsch, C Kunz, T Hielscher, ... haematologica 100 (7), 964, 2015 | 79 | 2015 |
| Application of 18F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities C Sachpekidis, J Mosebach, MT Freitag, T Wilhelm, EK Mai, ... American journal of nuclear medicine and molecular imaging 5 (5), 479, 2015 | 77 | 2015 |
| Single versus tandem high‐dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long‐term results from the phase III … EK Mai, A Benner, U Bertsch, P Brossart, A Hänel, V Kunzmann, ... British journal of haematology 173 (5), 731-741, 2016 | 72 | 2016 |
| Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG … H Goldschmidt, EK Mai, U Bertsch, R Fenk, E Nievergall, D Tichy, ... The Lancet Haematology 9 (11), e810-e821, 2022 | 59 | 2022 |
| A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma EK Mai, T Hielscher, JK Kloth, M Merz, S Shah, MS Raab, M Hillengass, ... Haematologica 100 (6), 818, 2015 | 57 | 2015 |
| Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained response N Lehners, N Becker, A Benner, M Pritsch, M Löpprich, EK Mai, ... Cancer medicine 7 (2), 307-316, 2018 | 52 | 2018 |
| Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology EK Mai, T Hielscher, JK Kloth, M Merz, S Shah, M Hillengass, B Wagner, ... European radiology 26, 3939-3948, 2016 | 47 | 2016 |
| Search for familial clustering of multiple myeloma with any cancer C Frank, M Fallah, T Chen, EK Mai, J Sundquist, A Försti, K Hemminki Leukemia 30 (3), 627-632, 2016 | 47 | 2016 |
| 18F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate C Sachpekidis, EK Mai, H Goldschmidt, J Hillengass, D Hose, L Pan, ... Clinical nuclear medicine 40 (6), e300-e307, 2015 | 47 | 2015 |
| Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial H Goldschmidt, EK Mai, J Dürig, C Scheid, KC Weisel, C Kunz, U Bertsch, ... Leukemia 34 (7), 1853-1865, 2020 | 46 | 2020 |
| Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma M Merz, T Hielscher, A Seckinger, D Hose, EK Mai, MS Raab, ... American journal of hematology 91 (11), E473-E477, 2016 | 42 | 2016 |
| A systematic classification of death causes in multiple myeloma EK Mai, EM Haas, S Lücke, M Löpprich, C Kunz, M Pritsch, ... Blood cancer journal 8 (3), 30, 2018 | 36 | 2018 |
| Elotuzumab in combination with lenalidomide, bortezomib, dexamethasone and autologous transplantation for newly-diagnosed multiple myeloma: results from the randomized phase … H Goldschmidt, EK Mai, U Bertsch, B Besemer, M Haenel, K Miah, R Fenk, ... Blood 138, 486, 2021 | 32 | 2021 |
